Using QTBI analysis, Harmon et al. [10] have found that total tumor burden determining a SUVtotal metric via bone segmentation followed by thresholding the NaF SUV at 15g/mL has been valuable in assessing response in mCRPC patients using an effective therapy, such as androgen receptor pathway inhibitors or a docetaxel-based chemotherapy regimen. Here, AR is linked to neoplasm.